Aerie's Rocket misfires in glaucoma

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) fell $23.01 (65%) to $12.38 in after hours trading Thursday after it said Rhopressa ( AR-13324) missed the primary endpoint of the Phase III Rocket 1 trial to treat intraocular pressure in patients with glaucoma or ocular hypertension.

Rhopressa failed to show non-inferiority to adrenergic receptor beta ( ADRB) blocker timolol in lowering IOP, the primary endpoint, in glaucoma patients with an IOP between 20 and 27 mmHg. ...